Abstract:Background: The use of rivaroxaban in clinical practice often deviates from manufacturer prescribing information. No studies have demonstrated an association between this practice and improved outcomes. Methods: We used the RIETE registry to assess the clinical characteristics of patients with pulmonary embolism (PE) who received off-label rivaroxaban, and to compare their 3-month outcomes with those receiving the labeled therapy. The patients were classified into four subgroups: (1) labeled therapy; (2) delay… Show more
“…New insights into the long-term treatment of VTE using DOACs such as rivaroxaban have been reported in this Special Issue. Additionally, patients that took rivaroxaban monotherapy for VTE according to dose regimens suggested and advised against in international guidelines were discussed by Di Micco et al [5]. Intriguing data were summarized in a review by Shah et al [6] regarding catheter-directed DVT treatments, helping to address the contemporary lack of randomized clinical studies in the literature [6].…”
“…New insights into the long-term treatment of VTE using DOACs such as rivaroxaban have been reported in this Special Issue. Additionally, patients that took rivaroxaban monotherapy for VTE according to dose regimens suggested and advised against in international guidelines were discussed by Di Micco et al [5]. Intriguing data were summarized in a review by Shah et al [6] regarding catheter-directed DVT treatments, helping to address the contemporary lack of randomized clinical studies in the literature [6].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.